CorMedix (NYSEAMERICAN:CRMD) issued its quarterly earnings data on Tuesday. The biotechnology company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02), Fidelity Earnings reports. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.13 million.
Shares of CRMD stock traded down $0.25 during midday trading on Wednesday, hitting $7.95. 548 shares of the company were exchanged, compared to its average volume of 498,911. CorMedix has a 52 week low of $1.90 and a 52 week high of $13.70.
CRMD has been the topic of a number of research analyst reports. HC Wainwright set a $14.00 price objective on shares of CorMedix and gave the stock a “buy” rating in a report on Tuesday, May 28th. TheStreet upgraded shares of CorMedix from a “d+” rating to a “c-” rating in a report on Friday, August 2nd. Finally, Zacks Investment Research lowered shares of CorMedix from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 30th.
CorMedix Company Profile
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
Recommended Story: What is the QQQ ETF?
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.